文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Anifrolumab: the new frontier in the treatment of genetic interferonopathies.

作者信息

Frémond Marie-Louise, David Clémence, Richez Christophe

机构信息

Department of Paediatric Hematology-Immunology and Rheumatology, Centre de Référence des Rhumatismes inflammatoires, maladies Auto-immunes et Interféronopathies Systémiques de l'Enfant RAISE, Necker-Enfants Malades Hospital, AP-HP, Paris, France

Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France.

出版信息

RMD Open. 2024 Sep 23;10(3):e004780. doi: 10.1136/rmdopen-2024-004780.

DOI:10.1136/rmdopen-2024-004780
PMID:39313304
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11418534/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/680f/11418534/c687f3c4005c/rmdopen-10-3-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/680f/11418534/c687f3c4005c/rmdopen-10-3-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/680f/11418534/c687f3c4005c/rmdopen-10-3-g001.jpg

相似文献

[1]
Anifrolumab: the new frontier in the treatment of genetic interferonopathies.

RMD Open. 2024-9-23

[2]
Normalized Interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in Patients with Type I Interferonopathies.

J Clin Immunol. 2024-10-23

[3]
Anifrolumab to treat a monogenic interferonopathy.

J Allergy Clin Immunol Pract. 2024-5

[4]
Anifrolumab: First Approval.

Drugs. 2021-10

[5]
[Pharmacological actions of anifrolumab (Saphnelo) and clinical trial results as a treatment for systemic lupus erythematosus].

Nihon Yakurigaku Zasshi. 2022

[6]
Anifrolumab in systemic lupus erythematosus.

Drugs Today (Barc). 2023-2

[7]
A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale.

Clin Exp Rheumatol. 2024-8

[8]
Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus.

Expert Rev Clin Immunol. 2024

[9]
Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.

Mod Rheumatol. 2021-1

[10]
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab.

Clin Pharmacokinet. 2023-5

引用本文的文献

[1]
Anifrolumab Attenuates Follicular Helper T Cell Activation in Patients with Systemic Lupus Erythematosus.

Int J Mol Sci. 2025-7-31

本文引用的文献

[1]
Successful Treatment of Stimulator of Interferon Genes-Associated Vasculopathy of Infantile Onset SAVI Syndrome With Anifrolumab.

JAMA Dermatol. 2024-8-1

[2]
Anifrolumab to treat a monogenic interferonopathy.

J Allergy Clin Immunol Pract. 2024-5

[3]
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.

Lancet Rheumatol. 2019-12

[4]
Anifrolumab for Adolescent Discoid Lupus Erythematosus.

JAMA Netw Open. 2023-10-2

[5]
Lung Transplantation under a Janus Kinase Inhibitor in Three Patients with SAVI Syndrome.

J Clin Immunol. 2023-11

[6]
Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus.

Expert Rev Clin Immunol. 2024

[7]
JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study.

J Clin Immunol. 2023-8

[8]
Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab?

Lupus. 2023-3

[9]
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.

Arthritis Rheumatol. 2023-2

[10]
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.

Ann Rheum Dis. 2022-7

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索